Mexico Lung Cancer Therapeutics Market Report 2022 to 2030

Mexico Lung Cancer Therapeutics Market Analysis

$ 3999

By 2030, it is anticipated that the Mexico Lung Cancer Therapeutics Market will reach a value of $850 Mn from $447 Mn in 2022, growing at a CAGR of 8.4% during 2022-2030. The Lung Cancer Therapeutics Market in Mexico is dominated by a few domestic pharmaceutical companies such as Silanes, Liomont, and PISA. The Lung Cancer Therapeutics Market in Mexico is segmented into different types of cancer and different therapy type. Some of the major factors affecting the Mexico lung cancer therapeutics market are the prevalence of unhealthy lifestyles, demand for targeted therapies and the presence of highly efficient drugs.

ID: IN10MXPH041 CATEGORY: Pharmaceuticals GEOGRAPHY: Mexico AUTHOR: Dr. Vishwa Modhia

Buy Now

Mexico Lung Cancer Therapeutics Analysis Summary

By 2030, it is anticipated that the Mexico Lung Cancer Therapeutics market will reach a value of $850 Mn from $447 Mn in 2022, growing at a CAGR of 8.4% during 2022-30.

Mexico is an upper middle-income, developing country located in North America with a North Pacific Ocean, Gulf of Mexico, and Caribbean Sea coastline. Mexico is populated by 123 Mn individuals, making it the third most populous country in America. Every year in Mexico, 190,667 incident cancer cases occur, of which 7811 are Lung cancer cases, with a normalised rate of 5.8. Lung cancer deaths in Mexico are more common in men, with a 1.6:1 ratio, and older age individuals, with 53 % of all deaths occurring in patients older than 70 years old, and impact the northern portion of the country more frequently.

According to the latest WHO data published in 2020 Lung Cancers Deaths in Mexico reached 7,349 or 1.19% of total deaths. The age-adjusted Death Rate is 6.21 per 100,000 population ranks Mexico 128^th in the world. Mexico's government spends 6.2% of its GDP on healthcare.

Mexico Lung Cancer Therapeutics Analysis

Market Dynamics

Market Growth Drivers

Radiation therapy is currently available in only two cities (Mexico City and Monterrey). Video-assisted thoracic surgery technology is now available nationwide. In Mexico, 1.6 Mn people continue to use biomass (especially wood) as an energy source for cooking and heating, contributing to an increase in lung cancer cases. Mexico is a vast country with a large population, is close to the American economy, and has low labour expenses. These aspects could boost Mexico's Lung Cancer Therapeutics market.

Market Restraints

The lung cancer burden in Mexico is evident. However, Mexican patients with lung cancer still suffer from shortcomings when considering several aspects pertaining to their health care. For example, there is currently no active public screening program for high-risk populations even though these risks are well characterized within the national setting. Mexico has significant economic disparities, a high incidence of labour informality, and rising criminality. In terms of therapeutic strategies, patients in Mexico have access to surgery; however, most patients who are candidates for surgery will be treated by a cardiothoracic surgeon, rather than by a thoracic oncology specialist. These factors may deter new entrants into the Mexico Lung Cancer Therapeutics market.

Competitive Landscape

Key Players

Laboratorios Silanes: Silanes is a Mexican pharmaceutical company that specializes in the development and production of innovative medicines for various health conditions, including cancer. They have a range of oncology products, including those for lung cancer
Laboratorios Liomont: Liomont is a Mexican pharmaceutical company that produces and markets a range of medicines for various therapeutic areas, including oncology
Laboratorios PISA: PISA is a Mexican pharmaceutical company that focuses on the development and production of generic medicines. They offer a range of oncology products, including those for lung cancer
Grupo Biotoscana: Biotoscana is a biopharmaceutical company that focuses on the development, production, and distribution of speciality and orphan drugs in Latin America
Rimsa: Rimsa is a Mexican pharmaceutical company that produces and distributes a range of prescription and over-the-counter medicines. They have a range of oncology products, including those for lung cancer

Recent Notable Updates

January 2023: The Federal Commission for the Protection against Sanitary Risks of Mexico (COFEPRIS) has granted full approval for the commercialization of Zepzelca (lurbinectedin) to PharmaMar's licencing partner, Adium Pharma, for the treatment of adult patients with metastatic Small Cell Lung Cancer (SCLC) who have disease progression on or after platinum-based chemotherapy. This latest approval of lurbinectedin is based on monotherapy clinical results from an open-label, multicenter, single-arm clinical trial in 105 adult patients with recurrent SCLC, which was used by the Food and Drug Administration (FDA) to grant lurbinectedin rapid approval in the US. PharmaMar and Adium Pharma struck a licencing agreement for lurbinectedin in Latin America in March 2021.

Healthcare Policies and Reimbursement Scenarios

In Mexico, lung cancer therapeutics are regulated by the Federal Commission for Protection against Sanitary Risks (COFEPRIS), which is responsible for approving drugs and medical devices for use in the country. The Mexican healthcare system is organised into two parts: public and private, with public facilities serving an overwhelming 93 % of the population. The Mexican Institute of Social Security (IMSS), which covers half of the population, the State Workers Institute for Social Security and Health (ISSSTE), and the most current Popular Health Insurance are examples (SPS).

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Lung Cancer Therapeutics Segmentation

By Type (Revenue, USD Billion):

Small Cell Lung Cancer
Non-small Cell Lung Cancer
Lung Carcinoid Tumor

By Therapy (Revenue, USD Billion):

Radiation Therapy
Targeted Therapy
Immunotherapy
Chemotherapy
Others

By Type of Molecule (Revenue, USD Billion):

Small Molecules
Biologics

By Drug Class (Revenue, USD Billion):

Alkylating Agents
Antimetabolites
Multikinase Inhibitors
Mitotic Inhibitors
EGFR Inhibitors
Others

By Distribution Channel (Revenue, USD Billion):

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.